ReviewFrontiers in pharmacology2021
Natural Products Targeting Liver X Receptors or Farnesoid X Receptor.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Polyphenols as Systems Modulators of the Gut-Brain-Liver Axis: A Narrative Review of Neuro-Metabolic and Immunomodulatory Networks.Molecular nutrition & food research · 2026Review
- Efficacy and safety of Korean red ginseng as adjunctive therapy in type 2 diabetes mellitus: a 12-week randomized, double-blind, placebo-controlled trial.Journal of ginseng research · 2026Article
- Development and Characterization of Intravenous Nanoemulsions Loaded withMolecules (Basel, Switzerland) · 2026Article
- Discovery of small molecule inhibitors of liver X receptor for pediatric metabolic disorders by structure based screening, modelling, dft analysis and MD simulation.Scientific reports · 2026Article
- Xanthohumol and its non-estrogenic derivatives link to the gut-liver-brain axis to improve cognition in mice with diet-induced obesity.Frontiers in physiology · 2026Article
- Ursodeoxycholic acid alleviates high-fat diet-induced liver injury by modulating gut microbiota-mediated bile acid metabolism: an integrated microbiota-metabolomics analysis.Frontiers in nutrition · 2026Article
- A therapeutic approach of LC-MS characterised MFER-Mc against alcohol and NDEA induced hepatocellular carcinoma activity through LXR-α, LXR-β and HMG-CoA pathway: an in-silico, in-vitro and in-vivo study.Medical oncology (Northwood, London, England) · 2025Article
- Increased intestinal permeability and bile acid accumulation via inhibition of the FXR-SHP pathway contribute to coumarin-induced systemic inflammation.Microbiology spectrum · 2025Article
- Bioactive Glycosylated Flavonoids Exhibiting LXR Agonist Activity from a Lauraceae Colombian Species.Plants (Basel, Switzerland) · 2025Article
- Natural Product-Induced Modulation of Androstenone Metabolism in Porcine Hepatocytes.Animals : an open access journal from MDPI · 2025Article
- Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: Focus on PPARs, LXRs, and PCSK9.Atherosclerosis plus · 2025Review
- Ameliorative Effect of Herbal Medicine in the Management of Hepatotoxicity.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Antioxidant Potential of Xanthohumol in Disease Prevention: Evidence from Human and Animal Studies.Antioxidants (Basel, Switzerland) · 2024Review
- New Sesquiterpenoids from the Mangrove-Derived FungusMarine drugs · 2024Article
- LXR agonism for CNS diseases: promises and challenges.Journal of neuroinflammation · 2024Review
- Future therapeutic perspectives in nonalcoholic fatty liver disease: a focus on nuclear receptors, a promising therapeutic target.Medicine and pharmacy reports · 2024Review
- Overview of Ursolic Acid Potential for the Treatment of Metabolic Disorders, Autoimmune Diseases, and Cancers via Nuclear Receptor Pathways.Biomedicines · 2023Review
- Harnessing Oleanolic Acid and Its Derivatives as Modulators of Metabolic Nuclear Receptors.Biomolecules · 2023Review
- Lonicera Caerulea Juice Alleviates Alcoholic Liver Disease by Regulating Intestinal Flora and the FXR-FGF15 Signaling Pathway.Nutrients · 2023Article
- Evaluating the Magnolol Anticancer Potential in MKN-45 Gastric Cancer Cells.Medicina (Kaunas, Lithuania) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuclear receptors (NRs) are a superfamily of transcription factors induced by ligands and also function as integrators of hormonal and nutritional signals. Among NRs, the liver X receptors (LXRs) and farnesoid X receptor (FXR) have been of significance as targets for the treatment of metabolic syndrome-related diseases. In recent years, natural products targeting LXRs and FXR have received remarkable interests as a valuable source of novel ligands encompassing diverse chemical structures and bioactive properties. This review aims to survey natural products, originating from terrestrial plants and microorganisms, marine organisms, and marine-derived microorganisms, which could influence LXRs and FXR. In the recent two decades (2000-2020), 261 natural products were discovered from natural resources such as LXRs/FXR modulators, 109 agonists and 38 antagonists targeting LXRs, and 72 agonists and 55 antagonists targeting FXR. The docking evaluation of desired natural products targeted LXRs/FXR is finally discussed. This comprehensive overview will provide a reference for future study of novel LXRs and FXR agonists and antagonists to target human diseases, and attract an increasing number of professional scholars majoring in pharmacy and biology with more in-depth discussion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.